Opinion|Videos|September 25, 2023

Data Review of the Efficacy and Safety of Vismodegib in Advanced Basal Cell Carcinoma (EVRIANCE Trial)

Lilia Correa-Selm, MD, FAAD, FACMS, reviews the clinical trial data relating to the EVRIANCE study examining the use of vismodegib treatment in patients with locally advanced basal cell carcinoma, highlighting key efficacy and safety endpoints.

Jonathan S Zager, MD, FACS, FSSO

Moffitt Cancer Center

Tampa, Florida

Lilia Correa-Selm, MD, FAAD, FACMS

Moffitt Cancer Center

Tampa, Florida

Aaron Farberg, MD

Bare Dermatology

Dallas, Texas

John Strasswimmer, MD, PhD

Florida Atlantic University

Delray Beach, Florida

Andrew Weinstein, MD, MPH, FAAD

Boynton Beach Skin, University of Miami

Boynton Beach and Coral Gables, Florida

Series Description: Experts in dermatology discuss the clinical trial data from the BOLT and EVRIANCE clinical trials and review patient cases related to the management of patients with locally advanced basal cell carcinoma treated with sonidegib and vismodegib.

Segment Description: Lilia Correa-Selm, MD, FAAD, FACMS, reviews the clinical trial data relating to the EVRIANCE study examining the use of vismodegib treatment in patients with locally advanced basal cell carcinoma, highlighting key efficacy and safety endpoints.

Newsletter

Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.


Latest CME